BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pellicelli AM, Pace Palitti V, Vignally P, Ceccherini-Silberstein F, Siciliano M, Giannelli V, Moretti A, Tarquini P, Scifo G, Messina V, Ascione A, Izzi A, Marignani M, D'Ambrosio C, Fondacaro L, Ettorre GM, Ialongo P, Sacco R, Perno CF, Barbarini G; CLEO Group. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver Int 2017;37:653-61. [PMID: 27782373 DOI: 10.1111/liv.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
2 Aguiar BF, Campos GRF, Rodrigues JPV, Marques NN, Molina BF, Bittar C, Souza FF, Martinelli ALC, Rahal P, Pereira LRL. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil. Clin Res Hepatol Gastroenterol 2020;44:329-39. [PMID: 31523019 DOI: 10.1016/j.clinre.2019.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R; STIly Study Group. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. Medicine (Baltimore) 2018;97:e11307. [PMID: 29979400 DOI: 10.1097/MD.0000000000011307] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Fabrizio C, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G. The elderly and direct antiviral agents: Constraint or challenge? Dig Liver Dis. 2017;49:1036-1042. [PMID: 28651903 DOI: 10.1016/j.dld.2017.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Dig Liver Dis 2020;52:190-8. [PMID: 31813755 DOI: 10.1016/j.dld.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Perazzo H, Jorge MJ, Silva JC, Avellar AM, Silva PS, Romero C, Veloso VG, Mujica-Mota R, Anderson R, Hyde C, Castro R. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterol 2017;17:119. [PMID: 29169329 DOI: 10.1186/s12876-017-0676-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pariente A, Arpurt JP, Remy AJ, Rosa-Hezode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le-Bricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagege H, Lesgourgues B; Association Nationale des Gastroenterologues des Hopitaux (ANGH). Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals. Ann Hepatol 2019;18:193-202. [PMID: 31113590 DOI: 10.5604/01.3001.0012.7912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forné M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia AC, Blasco A, López-Núñez C, Sánchez-Ruano JJ, Gea-Rodríguez F, Giráldez Á, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons V, Forns X. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int 2017;37:1823-32. [PMID: 28481460 DOI: 10.1111/liv.13470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
9 Pan CQ, Gayam V, Rabinovich C, Normatov M, Fidman B, Wang D, Garlapati P. Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. J Am Geriatr Soc 2020;68:379-87. [PMID: 31647119 DOI: 10.1111/jgs.16206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Ippolito AM, Iacobellis A, Milella M, Conti F, Messina V, Valvano MR, Niro GA, Morisco F, Barone M, Termite AP, Brancaccio G, Andriulli A. Hepatitis C Virus Clearance in Older Adults. J Am Geriatr Soc 2018;66:85-91. [PMID: 29135030 DOI: 10.1111/jgs.15140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]